| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of 3FAx-Neu5Ac is sialyltransferase, the enzyme responsible for transferring sialic acid to glycoconjugates. As a sialic acid analog, the compound acts as a sialyltransferase inhibitor. By inhibiting sialyltransferase, it reduces the expression of sialylated glycans such as sialyl Lewis X on cell surfaces. This affects cell adhesion, immune cell trafficking, and viral interactions.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that 3FAx-Neu5Ac substantially reduces the expression of the sialylated ligand sialyl Lewis X on myeloid cells. As a sialyltransferase inhibitor, it blocks the transfer of sialic acid to glycoconjugates, leading to reduced sialylation of cell surface glycans. This affects cell adhesion and immune cell interactions. The compound's unique structure provides insights into glycan-mediated processes.
|
| ln Vivo |
In vivo activity data for 3FAx-Neu5Ac are limited, as the compound is primarily used as a tool compound in glycobiology research. Its effects on sialylation and immune function may be relevant in vivo for studying cell adhesion, immune responses, and inflammation. However, specific in vivo studies have not been extensively reported in the available literature.
|
| Enzyme Assay |
Non-cellular assays for 3FAx-Neu5Ac typically involve measuring its inhibitory activity against purified sialyltransferase enzymes. The compound is incubated with the enzyme and its substrates (CMP-sialic acid and acceptor glycoconjugate), and the transfer of sialic acid is measured using radiometric or fluorometric methods. IC50 values are determined from dose-response curves. These cell-free systems allow for characterization of the compound's inhibitory potency.
|
| Cell Assay |
Cellular assays for 3FAx-Neu5Ac are conducted using myeloid cell lines or other cells expressing sialyltransferases. Cells are treated with the compound, and the expression of sialylated ligands such as sialyl Lewis X is measured by flow cytometry or ELISA. Cell adhesion assays are used to assess the functional effects of reduced sialylation. These studies demonstrate the compound's ability to modulate cell surface sialylation.
|
| Animal Protocol |
In vivo animal experiments for 3FAx-Neu5Ac may be conducted in models of inflammation, immune responses, or cancer metastasis. The compound is administered via injection, and its effects on immune cell trafficking, tumor metastasis, or inflammatory responses are assessed. However, specific in vivo studies have not been extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3FAx-Neu5Ac are not well-characterized. The compound has a molecular weight of 551.47 g/mol and is typically stored at -20°C. Its peracetylated nature may enhance cell permeability, allowing it to enter cells and be deacetylated to the active form. Its stability in biological fluids and its distribution in vivo have not been extensively studied.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3FAx-Neu5Ac are limited, as it is a research reagent not intended for human use. Standard laboratory safety precautions should be followed when handling the compound. No significant toxicity has been reported at the concentrations used in research studies. The compound is for research use only.
|
| References | |
| Additional Infomation |
Other information includes 3FAx-Neu5Ac's role as a peracetylated analog of sialic acid and a sialyltransferase inhibitor. It substantially reduces the expression of the sialylated ligand sialyl Lewis X on myeloid cells. It is used as a tool compound in glycobiology research to study cell adhesion, immune responses, and viral interactions. The compound is also known as P-3FAX-Neu5Ac and methyl 5-acetamido-2,4-diacetyloxy-3-fluoro-6-[(1S,2R)-1,2,3-triacetyloxypropyl]oxane-2-carboxylate.
|
| Molecular Formula |
C22H30FNO14
|
|---|---|
| Molecular Weight |
551.47
|
| Exact Mass |
551.165
|
| CAS # |
117405-58-0
|
| PubChem CID |
72698605
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
606.3±55.0 °C at 760 mmHg
|
| Flash Point |
320.5±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.493
|
| LogP |
1.65
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
38
|
| Complexity |
954
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=O)NC1C(C(C(OC1[C@@H]([C@@H](COC(=O)C)OC(=O)C)OC(=O)C)(C(=O)OC)OC(=O)C)F)OC(=O)C
|
| InChi Key |
COXHVKPJIOSDPS-RTEYEINBSA-N
|
| InChi Code |
InChI=1S/C22H30FNO14/c1-9(25)24-16-18(17(35-12(4)28)15(34-11(3)27)8-33-10(2)26)38-22(21(31)32-7,37-14(6)30)20(23)19(16)36-13(5)29/h15-20H,8H2,1-7H3,(H,24,25)/t15-,16?,17-,18?,19?,20?,22?/m1/s1
|
| Chemical Name |
methyl 5-acetamido-2,4-diacetyloxy-3-fluoro-6-[(1S,2R)-1,2,3-triacetyloxypropyl]oxane-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8133 mL | 9.0667 mL | 18.1334 mL | |
| 5 mM | 0.3627 mL | 1.8133 mL | 3.6267 mL | |
| 10 mM | 0.1813 mL | 0.9067 mL | 1.8133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
